Bragar Eagel & Squire, P.C. said a securities class action was filed in the U.S. District Court for the Central District of California against Beta Bionics, Inc. on behalf of investors who purchased or otherwise acquired the company’s common stock during the proposed Class Period. The lawsuit alleges that Beta Bionics made materially false or misleading statements about its iLet Bionic Pancreas automated insulin delivery system and failed to disclose serious device malfunctions, insulin overdosing and related hypoglycemic events. The allegations say complaints back-filed with the FDA numbered in the thousands and included hundreds of life-threatening events requiring significant medical intervention, while the company failed to implement meaningful corrective actions. Earlier complaints from Kaplan Fox & Kilsheimer LLP and Glancy Prongay Wolke & Rotter LLP cited more than 18,000 complaints, FDA-related safety and reporting issues, and a 37% stock-price decline after a January 8, 2026 patient-starts miss. Investors have until November 3, 2026, to seek lead-plaintiff appointment; no class has been certified, and investors may remain absent class members without taking action.